Doxycycline

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Doxycycline

Examples of brand names: Vibramycin [DE]

ATC code: J01AA02

Main use (for orientation): Bacterial infections

Documented research summary

Pure CBD altered doxycycline cytotoxicity in a 72-hour cell experiment differently according to cell line and concentration. No general protective effect or human pair interaction established.

Uncertainties and limitations

Do not directly extrapolate tumour/immortalised cell lines and nominal concentrations to human organ toxicity; a laboratory finding is not treatment guidance. Missing data do not establish safety.

Separately recorded findings

1 separately recorded finding. Each statement applies to its documented study context.

CBD – laboratory and animal studies

Finding ID: B0448

Type of result: Pharmacodynamics; cell/concentration-dependent cytotoxicity

Observation: Synergistic cytotoxicity in SH-SY5Y; additive/antagonistic effects in HepG2, and antagonistic effects at low CBD concentration and additive effects at higher concentration in HEK293.

Mechanism: Combined effects on cell viability, membrane integrity and related laboratory endpoints

Study type: 72-hour cell-culture experiment

Context studied: Doxycycline 1.56–200 µg/ml; CBD reference standard 1.56 or 3.125 µg/ml; three independent experiments.

Clinical interpretation: Limited preclinical toxicity finding, not a quantified clinical risk.

Limitations and uncertainties: No general protective effect; tumour/immortalised cell lines instead of humans, nominal concentrations instead of free tissue exposure. No therapeutic antitumour claim.

Original sources for this finding: The Action of Cannabidiol on Doxycycline Cytotoxicity in Human Cells-In Vitro Study. [VE_MED_41226279]

References and access status

[VE_LABEL_D0288] DOXYCYCLINE (DOXYCYCLINE HYCLATE) TABLET, COATED [PD-RX PHARMACEUTICALS, INC.]

Original source / bibliographic reference

Authors: Respective marketing authorisation holder; regulatory product information

Year: 2026

Source type: Product information / SmPC / US Prescribing Information

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[VE_MED_41226279] The Action of Cannabidiol on Doxycycline Cytotoxicity in Human Cells-In Vitro Study.

Original source / bibliographic reference

Authors: Radko L, Wojciechowicz T, Kończak O, Żakowicz P, Łętowski O, Salmanowicz J, Skrzypczak Z.

Year: 2025

Source type: research-article; Journal Article

DOI: 10.3390/molecules30214319

PMID: 41226279

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – full-text access according to the literature database – Archive attribution confirmed by Europe PMC metadata. Direct retrieval was not fully verified here; access may require a browser check.

Europe PMC – full-text access according to the literature database – Listed as freely available HTML full text in the official Europe PMC metadata. Direct retrieval was not fully verified here.

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility